Unknown

Dataset Information

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?


ABSTRACT: Pancreatic resection still represents the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). However, the association with modern chemotherapy regimens is a key factor in improving the inauspicious oncological outcome. The benefit of neoadjuvant treatment (NAT) for borderline resectable/locally advanced PDAC has been demonstrated; this evidence raises the question of whether even resectable PDAC should undergo NAT rather than upfront surgery. NAT may avoid futile surgery because of undetected distant metastases or aggressive tumor biology, providing more effective systemic control of the disease, which is hampered when adjuvant chemotherapy is delayed or precluded. However, recent data show controversial results regarding the efficacy and safety of NAT i

SUBMITTER: Vivarelli M 

PROVIDER: S-EPMC9195424 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature